There is an insufficient clinical experience to evaluate the risk of hypersensitivity to idarucizumab discontinue if a serious hypersensitivity reaction occurs.
Patients treated with dabigatran have underlying disease states that predispose them to thromboembolic events reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease to reduce this risk, resume anticoagulant therapy as soon as medically appropriate.
0 kommentar(er)
